Latest Conference Articles

The COVID-19 pandemic has increased the usage of telemedicine tools in all medical fields.

Children treated with SSRIs and SGAs concurrently demonstrate higher waist circumference, BMI, and plasma total cholesterol compared to those on monotherapy.

Over half of patients attained target A1C <7%. while a third of patients attained target A1C of <8%.

Overweight/obese patients with elevated fasting blood glucose generally present with higher degrees of insulin resistance, inflammation, adverse cardiovascular disease risk profile.

New findings show patients were able to more than halve type 2 diabetes medication while improving diabetic and cardiovascular parameters in 8 weeks.

New SUPRASS-2 findings show the dual GIP/GLP-1 agonist provided superior type 2 diabetes management outcomes at 3 different doses.

Data show no evidence of increased risk of adverse events in patients aged ≥80 years, compared to patients aged 70 - 79 years.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The study author joins to highlight new ADA 2021 findings showing rivaroxaban's benefit for a subpopulation of diabetic patients.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

New data presented at ADA 2021 show GLP-1RA treatment is budget neutral in comparison to SoC, citing lower inpatient and outpatient cost.

New data show liraglutide reduced visceral, ectopic fat, with greater effects seen compared to weight loss.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Data presented at ADA 2021 supports the noninferiority of faricimab to aflibercept.

It could take up to 10 years to develop new treatments for inflammatory bowel disease.

Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.

Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.

Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.

A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.

Arena Pharmaceuticals expects to move forward with later phase clinical trials testing etrasimod.

Patients with opioid-induced constipation had more frequent, painful constipation symptoms, compared to those with chronic idiopathic constipation.

Direct optical endoscopy are often underutilized in screenings for EAC.

Data show patients with IBD and pathogen produced a unique pathogen-specific microbiome.

Dr. Evan Dellon said up to 8 biopsies for high risk patients could be beneficial in diagnosing different diseases impacting the esophagus.

Sucrase isomaltase deficiency is often overlooked symptom in adult patients with IBS-D.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.